Compass Therapeutics Inc [CMPX] stock is trading at $1.58, up 1.28%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CMPX shares have gain 8.22% over the last week, with a monthly amount glided 4.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Compass Therapeutics Inc [NASDAQ: CMPX] stock has seen the most recent analyst activity on December 23, 2024, when D. Boral Capital initiated its Buy rating and assigned the stock a price target of $32. Previously, Leerink Partners downgraded its rating to Market Perform on November 15, 2024, and dropped its price target to $4. On September 16, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $5 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $8 on January 31, 2023. Stifel initiated its recommendation with a Buy and recommended $9 as its price target on January 27, 2023. In a note dated March 15, 2022, Ladenburg Thalmann initiated an Buy rating and provided a target price of $7 on this stock.
Compass Therapeutics Inc [CMPX] stock has fluctuated between $0.76 and $2.34 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Compass Therapeutics Inc [NASDAQ: CMPX] shares were valued at $1.58 at the most recent close of the market. An investor can expect a potential return of 216.46% based on the average CMPX price forecast.
Analyzing the CMPX fundamentals
Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -15.01%, Pretax Profit Margin comes in at -12.93%, and Net Profit Margin reading is -12.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.32 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5333 points at the first support level, and at 1.4867 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6183, and for the 2nd resistance point, it is at 1.6567.
Ratios To Look Out For
For context, Compass Therapeutics Inc’s Current Ratio is 31.84. In addition, the Quick Ratio stands at 31.84 and the Cash Ratio stands at 8.3. Considering the valuation of this stock, the price to sales ratio is 284.98, the price to book ratio is 1.57.
